Navigation Links
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
Date:5/26/2009

-- Conference Call Scheduled for Monday June 1 at 1:00 PM ET to Discuss ASCO Data Presentations --

SOUTH SAN FRANCISCO, Calif., May 26 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that updated interim data from the Company's ongoing Phase 2 clinical trials in frontline acute myeloid leukemia (AML) and platinum-resistant ovarian cancer and its Phase 1b/2 clinical trial in relapsed/refractory AML will be presented during the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting in Orlando, Florida, which begins May 29, 2009. Following are the details on each of these data presentations.

               Saturday May 30, 8:00AM to 12:00PM (poster presentation)
               Abstract #7048
               Title: "A phase II study of voreloxin as single agent therapy
               for elderly patients (pts) with newly diagnosed acute myeloid
               leukemia (AML)."
               Location: Level 2, West Hall C
               Board #M2

               Sunday May 31, 2:00PM to 6:00PM (poster presentation)
               Abstract #5559
               Title: "A phase II trial of voreloxin in women with
               platinum-resistant ovarian cancer."
               Location: Level 2, West Hall C
               Board #M18

               Monday June 1, 10:30AM (oral presentation)
               Abstract #7005
               Title: "Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD)
               study of combination voreloxin and cytarabine in relapsed or
               refractory AML patients."
               Location: Level 2, West Hall F1

Additionally at the ASCO 2009 Annual Meeting, Sunesis will be presenting clinical
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. Sunesis Reports Financial Results for the First Quarter 2009
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... (PRWEB) August 01, 2014 Stryker ... wake of the 2012 Rejuvenate and ABG II ... in New Jersey’s Bergen County Superior Court, Bernstein ... the proceeding, the Court has issued a ... any and all hard copy and electronic materials ...
(Date:8/1/2014)... Ohio In a first-of-its-kind study, researchers at University ... that lap infants may be at greater risk for ... pediatric medical emergencies on flights worldwide between January 2010 ... occurred in children under the age of 2. ... to characterize the rare event of an in-flight pediatric ...
(Date:8/1/2014)... 2014 The evolving healthcare landscape ... pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor ... and resources to enhance patient care and profitability. ... critical issues to give independent pharmacists the tools ... , ThoughtSpot show attendance experienced a nearly 70% ...
(Date:8/1/2014)... down fears, emotions and the benefits of a cancer ... survivors, according to a study conducted by a researcher ... key to developing an expressive writing intervention is the ... recording facts and events. Writing a journal can be ... to determine whether it,s effective or not," said Qian ...
(Date:8/1/2014)... August 01, 2014 Market Publishers ... reports have been added to its catalogue. ... Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services ... pharma industry drivers include, among others, increasing ageing ... hygiene. In 2015, the pharma market in India ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3
... harming long-term survival, study suggests , , WEDNESDAY, April 9 ... cancer patient survival suggests it might be time to ... A team of New York City physicians found about ... of cancerous cells in their sentinel lymph nodes were ...
... 9, 2008 Global Health Council, the,world,s ... by improving,health throughout the world, will implement ... and Vermont locations., Organizational challenges prompted ... new software system to manage their core ...
... (Pink Sheets: BIEL), announced today that the company ... (TM) technology on,Bloomberg Television, April 14, 2008. The ... the informational commercial to run for,the next two ... CEO Andrew,Whelan comments, "This is a new initiative ...
... 1978-2008, WASHINGTON, April 9, 2008 Following ... March 2008:, The "Bulletin," which is free ... http://www.ncd.gov ), brings you the latest issues and ... NCD listserv, go to, http://listserv.access.gpo.gov, click on ...
... April 9 The Massage Spot,announced today that ... Manhattan,Beach, California, one block from the beach in ... expand the mini day spa concept of "affordable,luxury" ... currently looking,for investors interested in business partnerships and ...
... statement was,issued today by the law firm of Schiffrin Barroway ... a class action lawsuit was filed in the,United States District ... of all purchasers of securities of Humana Inc. (NYSE:,HUM) ("Humana" ... inclusive (the "Class Period")., If you wish to discuss ...
Cached Medicine News:Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 2Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 3Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 4Health News:Global Health Council Selects Aptify's Association Management Software 2Health News:Global Health Council Selects Aptify's Association Management Software 3Health News:BioElectronics Corporation's New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide 2Health News:National Council on Disability Monthly Bulletin for March 2008 2Health News:National Council on Disability Monthly Bulletin for March 2008 3Health News:The Massage Spot Announces Opening of Manhattan Beach Location; Seeks Investors for Growth of 'Affordable Luxury' Mini Day Spa Concept 2Health News:The Massage Spot Announces Opening of Manhattan Beach Location; Seeks Investors for Growth of 'Affordable Luxury' Mini Day Spa Concept 3Health News:Shareholder Class Action Filed Against Humana Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Humana Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3
(Date:8/1/2014)... 2014 Research and Markets ... Medical Biosensors Market 2014-2018" report to their ... Medical biosensors are used to analyze ... These biosensors monitor health status, disease betterment, and ... They are cost-effective and user-friendly devices. Also, they ...
(Date:8/1/2014)... , Aug. 1, 2014 MGC Diagnostics ... company, announced today that it has completed its ... of cardiorespiratory diagnostic products based in Sorinnes, ... served the European cardiorespiratory diagnostics market since 1977. ... of approximately €4.7 million ($6.3 million) and incurred ...
(Date:8/1/2014)... 1, 2014  Neuland Laboratories Ltd., (NSE:NEULANDLAB; BSE-Scrip ... ingredients (APIs), complex intermediates and custom ... countries, today announced financial results for the first ... 30, 2014. "Neuland,s results in the ... to accommodate certain customer needs, and we do ...
Breaking Medicine Technology:Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3
... presented at Israel Society of Nephrology Conference ... months from single treatment - Data continue to ... expensive injections MISGAV, Israel and LONDON, March 27 ... latest, encouraging results of the Company,s ongoing EPODURE Biopump ...
... of Clinical Lipidology publishes largest study comparing cancer ... using FDA database -BOSTON, March 25 A ... ezetimibe mono and ezetimibe/simvastatin combination treatments, compared to ... The study, conducted by Tufts Medical Center ...
Cached Medicine Technology:Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 2Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 3Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 4Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows 2
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
... Clinical Reference Laboratories at National Jewish ... general and specialized testing for clients ... diagnostic reference laboratories, they provide comprehensive, ... areas of immunology and flow cytometry, ...
Disposable Microscissors: Horizontal Curved Microscissors...
Sharp tipped illuminated scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and...
Medicine Products: